EDWARD TOBINICK MD
links: Dr. Tobinick's patented* new anti-TNF method for treating Alzheimer's disease(website) as discussed on the BBC, New Scientist, Nature Clinical Practice Neurology, and Reuters Health
Edward Tobinick is a California physician who has invented novel treatment approaches for a variety of medical conditions with widespread unmet medical need[1,2,3]. These conditions include Alzheimer's Disease and other forms of dementia; several forms of severe back and neck pain (including sciatica and cervical radiculopathy); a variety of additional neurological disorders; and pain due to cancer metastasis to the spine. Common to all of these conditions is the central involvement of inflammatory processes. Through May 2007 Dr. Tobinick has been awarded twelve U.S. patents for these new methods of treatment. His published papers have been cited in more than 150 scientific articles from leading academic centers around the world. His scientific work has been presented at medical conferences both in the U.S. and abroad. Major academic medical centers are currently involved in collaborative research with him to investigate his unique methods designed to deliver large molecules across the blood-brain barrier. In 2007 the anti-TNF pilot study for Alzheimer's Disease[1] conducted by Dr. Tobinick and his colleagues was recognized and cited by the prestigious Dana Alliance for Brain Initiatives in their Progress Report on Brain Research[4] and by a review article discussing the therapeutic potential of TNF-alpha inhibition as a treatment strategy for Alzheimer's disease and other neurodegenerative diseases by Nigel Grieg from the National Institute on Aging, National Institutes of Health, and his colleagues[5]. In 2008, a case-report he co-authored documenting rapid clinical improvement in a patient with dementia following perispinal administration of etanercept, a treatment method he invented, has received considerable interest[6, 7].

Dr. Tobinick graduated from Brandeis University in Waltham, Massachusetts, received his M.D. from the University of California San Diego School of Medicine in La Jolla, California, and completed post-graduate residencies at UCLA. He is currently the Medical Director of the Institute for Neurological Research, a private medical group, inc. at 100 UCLA Medical Plaza in Los Angeles and Assistant Clinical Professor of Medicine at UCLA.

[1] Edward Tobinick MD; Hyman Gross MD, Clinical Professor of Neurology, USC; Alan Weinberger MD, Associate Clinical Professor of Medicine/Rheumatology; Hart Cohen MD, FRCPC, Associate Clinical Professor of Medicine/Neurology. TNF Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot Study. Medscape General Medicine, 2006. 8(2):25. (Note: The use of etanercept for the treatment of Alzheimer's Disease is the subject of multiple U.S. patents awarded to Dr. Tobinick, including 6177077, 6982089, and 7214658).
[2]Tobinick, E. and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85. (Note: The use of etanercept for the treatment of sciatica and other forms of disc-related pain is the subject of multiple U.S. patents awarded to Dr. Tobinick, including 6015557, 6537549, and 6982089).
[3]Tobinick, E.L., Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther, 2003. 25(8): p. 2279-88.

[4]see "About the Dana Alliance for Brain Initiatives..." below.

[5]Tweedie, D., K. Sambamurti, and N.H. Greig, TNF-alpha Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Curr Alzheimer Res, 2007. 4(4): p. 375-8.

[6]Tobinick, E.L. and H. Gross, Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation, 2008. 5(1): p. 2. [link to full-text PDF].

[7]Griffin, W.S., Perispinal etanercept: Potential as an Alzheimer therapeutic. J Neuroinflammation, 2008. 5(1): p. 3.] [link to full-text PDF].

The graphic immediately below contains images and data generated by Dr. Tobinick's research. Please click on the graphic for further explanation:
Contact information for Dr. Tobinick: Telephone (310) 824-6191. Facsimile: (310) 824-6196. e-mail: etmd@ucla.edu
Further information:

Scientific articles authored by Dr. Tobinick (webpage)

Citations to Dr. Tobinick's scientific publications

The INR® website

A detailed scientific biography and bibliography for Edward Tobinick MD(PDF)

TNFMedicine.com

Patents issued to Edward Tobinick MD(PDF)

[4]ABOUT THE DANA ALLIANCE FOR BRAIN INITIATIVES: More than 260 neuroscientists comprise the Alliance membership, joined by the common interest in advancing public awareness about brain research. Recognized as leaders in their respective fields, they are among the world's foremost authorities on neuroscientific research and clinical neurology topics. Among the current members, 10 have received the Nobel Prize. The 2007 Progress Report on Brain Research is available online on the website of the Dana Foundation, at www.dana.org.
Copyright ©2008, the Institute for Neurological Research® (INR®), a private medical group, inc. Methods of off-label use and administration of certain cytokine antagonists, including etanercept, for selected clinical disorders are patented inventions of Dr. Tobinick; these methods are neither sponsored nor endorsed by UCLA; rather all rights to these patented methods of treatment are retained exclusively by the INR. The INR conducts a private medical practice. *U.S. patents 6015557, 6177077, 6419934, 6419944, 6471961, 6537549, 6982089, 7214658 and additional issued and pending U.S. and foreign patents.
<Terms of Use>